Medytox said it has received product approval from Indonesian health authorities for its hyaluronic acid (HA) filler Atiere in three different types – classic, intensive, and volume.

Indonesia, known as the world’s largest Muslim-majority nation and the fourth most populous country globally, has seen a rising interest in K-beauty products, including Korean botulinum toxin and fillers.

This trend is driven by the increasing popularity of Korean beauty standards and products. Medytox plans to leverage its marketing experience with Neuramis, an HA filler that entered the Indonesian market in 2019, to rapidly establish Atiere in the market.

Notably, the company stressed that the introduction of Atiere in Indonesia holds particular significance for the company as it is the first HA filler product registered overseas from its Osong Plant 3 in North Chungcheong Province. 

“Indonesia is a market with a high interest in Korean culture, substantial purchasing power, and a significant number of consumers in their 30s and 40s who are keen on skin and beauty care products,” a Medytox official said. “Through Atiere, which is a product of Medytox’s unique R&D technology, we aim to not only strengthen our presence in Indonesia but also expand our reach in the global filler market.”-